Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents
- PMID: 1357650
- DOI: 10.1111/j.1600-0749.1990.tb00361.x
Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents
Abstract
Tumor cells often display alterations in their normal program of cellular differentiation. A promising approach for the treatment of cancer involves the induction of terminal differentiation and a loss of proliferative capacity in cancer cells. In human melanoma cells, the combination of mezerein (MEZ) and fibroblast interferon (IFN-beta), results in a rapid and irreversible suppression of cell growth with a concomitant increase in the synthesis of melanin. The induction of terminal differentiation is associated with alterations in the expression of several cellular genes, including fibronectin, ISG-15 and ISG-54, and changes in the expression of specific cell surface antigens, including intercellular adhesion molecule-1 (ICAM-1) and HLA Class I antigens. In the HO-1 human melanoma cell line, induction of terminal differentiation by MEZ plus IFN-beta results in an induction and/or increased expression of ICAM-1, HLA Class I antigens and HLA Class II antigens. IFN-beta and MEZ alone can modulate expression of these antigens to a lower extent than does the combination of compounds. Induction of terminal differentiation and the irreversible suppression of cell growth is not a prerequisite for antigenic modulation in HO-1 cells. This is indicated by the inability of immune interferon (IFN-gamma), a strong inducer of ICAM-1, HLA Class I antigens and HLA Class II antigens synthesis, or the combination of IFN-beta plus IFN-gamma which synergistically but reversibly suppresses HO-1 growth, to induce melanin synthesis or terminal differentiation in HO-1 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.Cancer Immunol Immunother. 1992;35(5):315-24. doi: 10.1007/BF01741144. Cancer Immunol Immunother. 1992. PMID: 1356626 Free PMC article.
-
Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells.Anticancer Res. 1986 Jul-Aug;6(4):765-74. Anticancer Res. 1986. PMID: 2944474
-
Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.Cancer Immunol Immunother. 1991;32(6):382-90. doi: 10.1007/BF01741333. Cancer Immunol Immunother. 1991. PMID: 1672507 Free PMC article.
-
Lymphocyte-melanoma interaction: role of surface molecules.Recent Results Cancer Res. 1995;139:205-14. doi: 10.1007/978-3-642-78771-3_15. Recent Results Cancer Res. 1995. PMID: 7597291 Review.
-
Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance.J Immunogenet. 1986 Apr-Jun;13(2-3):229-34. doi: 10.1111/j.1744-313x.1986.tb01105.x. J Immunogenet. 1986. PMID: 2434574 Review.
Cited by
-
RaSH, a rapid subtraction hybridization approach for identifying and cloning differentially expressed genes.Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12684-9. doi: 10.1073/pnas.220431297. Proc Natl Acad Sci U S A. 2000. PMID: 11058161 Free PMC article.
-
Defining the domains of human polynucleotide phosphorylase (hPNPaseOLD-35) mediating cellular senescence.Mol Cell Biol. 2005 Aug;25(16):7333-43. doi: 10.1128/MCB.25.16.7333-7343.2005. Mol Cell Biol. 2005. PMID: 16055741 Free PMC article.
-
Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.Cancer Immunol Immunother. 1992;35(5):315-24. doi: 10.1007/BF01741144. Cancer Immunol Immunother. 1992. PMID: 1356626 Free PMC article.
-
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.Pharmacol Ther. 2006 Sep;111(3):596-628. doi: 10.1016/j.pharmthera.2005.11.005. Epub 2006 Feb 7. Pharmacol Ther. 2006. PMID: 16464504 Free PMC article. Review.
-
Human polynucleotide phosphorylase (hPNPase(old-35)): an evolutionary conserved gene with an expanding repertoire of RNA degradation functions.Oncogene. 2011 Apr 14;30(15):1733-43. doi: 10.1038/onc.2010.572. Epub 2010 Dec 13. Oncogene. 2011. PMID: 21151174 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous